Jan 18, 2019 / Presentations Future policy directions to address Medicare prescription drug spending Research Areas: Drugs, Devices, and Tests
Jan 17, 2019 / Presentations The Medicare prescription drug program (Part D): Status report Research Areas: Drugs, Devices, and Tests, Private Plans
Jan 16, 2019 / Comment Letters MedPAC comment on CMS’s proposed rule on modernizing Part D and Medicare Advantage to lower drug prices and reduce OOP expenses Research Areas: Delivery System Reforms, Drugs, Devices, and Tests, Private Plans
Nov 28, 2018 / Comment Letters MedPAC comment on CMS’s proposed rule on requiring drug pricing transparency Research Areas: Delivery System Reforms, Drugs, Devices, and Tests
Nov 01, 2018 / Presentations Promoting greater Medicare-Medicaid integration in dual-eligible special-needs plans Research Areas: Drugs, Devices, and Tests, Private Plans
Oct 04, 2018 / Presentations Managing prescription opioid use in Medicare Part D Research Areas: Drugs, Devices, and Tests, Private Plans
Oct 04, 2018 / Presentations Opioids and alternatives in hospital settings: Payments, incentives, and Medicare data Research Areas: Drugs, Devices, and Tests, Hospitals
Sep 06, 2018 / Presentations Beneficiary enrollment in Medicare Research Areas: Beneficiaries and Coverage
Aug 31, 2018 / Comment Letters MedPAC comment on CMS’s proposed rule on the ESRD PPS update for CY 2019 and DMEPOS Competitive Bidding Program Research Areas: Ambulatory Care Settings, Delivery System Reforms, Drugs, Devices, and Tests, Quality
Jul 03, 2018 / Comment Letters MedPAC comment on HHS’s policy statement and RFI on the HHS blueprint to lower drug prices and reduce out-of-pocket costs Research Areas: Delivery System Reforms, Drugs, Devices, and Tests, Medicare Spending and Financing